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Abstract In the Phase 3 DEFINE study, delayed-release
dimethyl fumarate (DMF) 240 mg twice (BID) and three
times daily (TID) significantly reduced the mean number of
new or enlarging T2-hyperintense lesions and gadolinium-
enhancing (Gd?) lesion activity at 2 years in patients
(MRI cohort; n = 540) with relapsing–remitting MS. The
analyses described here expand on these results by con-
sidering additional MRI measures (number of T1-hypoin-
tense lesions; volume of T2-hyperintense, Gd?, and T1-
hypointense lesions; brain atrophy), delineating the time
course of the effects, and examining the generality of the
effects across a diverse patient population. Reductions in
lesion counts with delayed-release DMF BID and TID,
respectively, vs. placebo were apparent by the first MRI
assessment at 6 months [T2-hyperintense: 80 and 69 %
reduction (both P \ 0.0001); Gd?, 94 and 81 % reduction
(both P \ 0.0001); T1-hypointense: 58 % (P \ 0.0001)
and 48 % (P = 0.0005) reduction] and maintained at 1 and
2 years. Reductions in lesion volume were statistically
significant beginning at 6 months for T2-hyperintense
[P = 0.0002 (BID) and P = 0.0035 (TID)] and Gd?
lesions [P = 0.0059 (BID) and P = 0.0176 (TID)] and
beginning at 1 year [P = 0.0126 (BID)] to 2 years
[P = 0.0063 (TID)] for T1-hypointense lesions. Relative
reductions in brain atrophy from baseline to 2 years (21 %
reduction; P = 0.0449) and 6 months to 2 years (30 %
reduction; P = 0.0214) were statistically significant for
delayed-release DMF BID. The effect of delayed-release
DMF on mean number of new or enlarging T2-hyperin-
tense lesions and Gd? lesion activity was consistent across
pre-specified patient subpopulations. Collectively, these
results suggest that delayed-release DMF favorably affects
multiple aspects of MS pathophysiology.
For the DEFINE study investigators (See online supplement,
appendix e-1).
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Introduction
MRI is an important tool for monitoring MS disease
activity and progression in both clinical practice and clin-
ical trials [1, 2]. Gadolinium-enhancing (Gd?) lesion
counts on T1-weighted images, and new or enlarging T2-
hyperintense lesions, give an indication of recent inflam-
mation and may predict relapse rate in the short term [2, 3].
T2-weighted images allow a quantitation of the accumu-
lated extent, or overall burden, of focal white matter dis-
ease [1, 4], whereas chronic (unenhancing) T1-hypointense
lesions have been more strongly associated with tissue
destruction and axonal loss, and their persistence is asso-
ciated with increased disability and permanent neurological
deficit [5, 6]. Overall reduction in brain volume over time
is considered to be a marker of neurodegeneration, and
shows a relatively strong correlation with physical dis-
ability and cognitive impairment [7]. A goal of MS treat-
ment is to attenuate or delay these changes on MRI by
counteracting the inflammatory neurodegeneration and
demyelination that define the disease.
Delayed-release dimethyl fumarate (DMF; known as
Tecfidera in countries in which it is approved and referred
to as BG-12 during clinical development) is a novel oral
therapeutic tested in people with relapsing–remitting MS
(RRMS). Preclinical studies indicate that delayed-release
DMF exerts anti-inflammatory and neuroprotective effects
via activation of the nuclear factor (erythroid-derived 2)-
like2 (Nrf2) pathway [8, 9] and also via Nrf2-independent
mechanisms [10, 11]. In the randomized, placebo-con-
trolled, Phase 3 DEFINE trial, delayed-release DMF
240 mg twice (BID) and three times daily (TID) demon-
strated efficacy on clinical endpoints, including annualized
relapse rate, risk of relapse, and risk of confirmed disability
progression, combined with an acceptable safety profile,
over 2 years [12]. Delayed-release DMF also demonstrated
significant efficacy on MRI endpoints including mean
number of new or enlarging T2-hyperintense lesions (BID:
85 % reduction; TID: 74 % reduction; both P \ 0.001 vs.
placebo) and Gd? lesion activity (BID: 90 % reduction;
TID: 73 % reduction; both P \ 0.001 vs. placebo), at
2 years [12]. These findings were supported by the results
of a second Phase 3 trial, the CONFIRM study, which
additionally evaluated subcutaneous glatiramer acetate as
an active reference treatment (rater-blinded) [13].
The present analyses were conducted to expand on the
previously reported MRI results from the DEFINE study by
considering additional MRI measures, delineating the time
course of the effects, and examining the generality of the
effects across a diverse patient population. Here, we report
the effects of delayed-release DMF on the number of new
or enlarging T2-hyperintense lesions and number of Gd?
lesions at 6 months, 1 and 2 years; the number of new non-
enhancing T1-hypointense lesions at 6 months, 1 and
2 years; the volume of all T2-hyperintense, Gd?, and T1-
hypointense lesions at 6 months, 1 and 2 years; brain
atrophy at 2 years; and the number of T2-hyperintense and
Gd? lesions at 2 years in subgroups of patients stratified
by baseline demographic and disease characteristics.
Methods
Standard protocol approvals, registrations, and patient
consents
The DEFINE study (ClinicalTrials.gov identifier
NCT00420212) was approved by central and local ethics
committees and conducted in accordance with the Inter-
national Conference on Harmonisation Guidelines for
Good Clinical Practice [14] and the Declaration of Helsinki
[15]. All patients were fully informed of approved MS
therapies as an alternative to participation in a placebo-
controlled trial, and provided written informed consent and
re-consent after confirmed relapse or disability progression
(after discussion of treatment options as detailed below).
Patients
As reported previously [12], eligible patients were aged
18–55 years, with a diagnosis of RRMS, a baseline score of
0–5.0 on the Expanded Disability Status Scale (EDSS), and
disease activity defined by at least one clinically docu-
mented relapse within 12 months before randomization, or
a brain MRI scan with at least one Gd? lesion within
6 weeks before randomization. Key exclusion criteria
included progressive forms of MS, other major disease that
would preclude participation in a clinical trial, pre-speci-
fied abnormal laboratory results, or recent exposure to
contraindicated medications [12].
Study design
Patients were randomized 1:1:1 to receive double-blind
treatment with oral delayed-release DMF 240 mg BID or
TID or placebo [12]. Randomization was centralized and
stratified by site. Each study center used separate exam-
ining and treating neurologists who were blinded
throughout. The examining neurologist conducted neuro-
logical assessments while the treating neurologist was
responsible for all aspects of patient care, including the
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treatment of relapses and other disease symptoms. Patients
were eligible to switch to an alternative MS therapy if they
had completed 48 weeks of blinded treatment and experi-
enced C1 confirmed relapse after 6 months, or at any time
if they had experienced confirmed disability progression.
Study procedures and endpoints
As reported elsewhere, the primary endpoint was the
proportion of patients who had experienced an MS
relapse by 2 years [12]. Secondary MRI endpoints at
2 years included the number of new or enlarging T2-
hyperintense lesions and the number of Gd? lesions on
brain MRI. Tertiary endpoints included number of new or
enlarging T2-hyperintense lesions and number of Gd?
lesions at 1 year; number of new T1-hypointense lesions
at 1 and 2 years; volume of all T2-hyperintense, Gd?,
and T1-hypointense lesions at 1 and 2 years; and brain
atrophy at 2 years.
MRI
Brain MRI scans with and without gadolinium were
performed in patients from a subset of sites with full
MRI capabilities using a standardized acquisition super-
vised by the MRI reading center (NeuroRx Research,
Montreal, QC, Canada). Approximately 95 % of patients
at these sites chose to participate. MRI scans were
obtained at baseline (or any time between screening and
baseline) and 6 months, 1 and 2 years and were not to
be performed within 30 days of a course of steroids.
MRI scans provided full head coverage and included the
following sequences: PD- and T2-weighted 2D multislice
turbo/fast spin-echo, T1-weighted 3D spoiled gradient-
recalled echo (pre-contrast), 2D T2-weighted FLAIR, and
3D spoiled gradient-recalled echo T1-weighted (post-
contrast).
All original digital data for all MRI images were
transferred from each of the sites to the MRI reading center
for blinded evaluation. Lesion-based measurements per-
formed included: T2-weighted lesion count (at baseline);
new or enlarging T2-weighted lesion count (all post-base-
line visits); T2-weighted lesion volume (all MRI visits);
Gd? lesion count and volume (all MRI visits); T1-
weighted hypointense (non-enhancing) lesion count at
baseline; new T1-weighted non-enhancing lesion count (all
post-baseline visits); and total volume of non-enhancing
T1-weighted lesions (all MRI visits). T2-weighted lesions
were segmented using locally developed software [16] and
manually corrected as necessary. Lesions had to be at least
three voxels in size to be counted. T1 lesions were seg-
mented within T2-weighted lesions using a threshold of
85 % of the intensity of surrounding normal-appearing
white matter (which corresponded approximately to the
intensity of grey matter). Regions of acute T1 hypointen-
sity associated with gadolinium enhancement were
removed. Baseline lesions had to be surrounded by normal-
appearing tissue. New lesion counts were made relative to
the prior visit and added over time intervals as appropriate
to express results relative to baseline. For assessment of
brain atrophy, normalized brain volume was determined at
baseline, and percentage brain volume change (PBVC)
calculated automatically for each post-baseline MRI visit
relative to baseline.
Statistical analyses
The MRI cohort comprised patients who consented to
participate in MRI analysis and had any MRI data, and was
a subset of the overall study intention-to-treat (ITT) pop-
ulation (randomized patients who received at least one dose
of study treatment).
The numbers of new or enlarging T2-hyperintense and
new non-enhancing T1-hypointense lesions were analyzed
using a negative binomial regression model; the number of
Gd? lesions was analyzed using an ordinal logistic
regression model; and brain atrophy was analyzed using
percentage changes compared between treatment groups
using an analysis of covariance on ranked data. The ana-
lytical models included adjustments for region (defined by
type of healthcare system and access to healthcare, in
addition to geography) and baseline characteristics,
including number or volume of baseline lesions, as
appropriate.
For brain atrophy analyses, the pre-specified analysis of
interest was the PBVC from 6 months to 2 years. Six
months was chosen as the baseline reference time point
because in RRMS studies of therapies with anti-inflam-
matory properties, a greater relative decrease in brain
volume has been observed in the therapeutic agent arm
within the first several months of treatment, presumably
due to a greater reduction in inflammation and edema [17].
Adjustments were made for region and normalized brain
volume at the reference time point.
A sequential (closed) testing procedure was used to
control the overall type I error rate due to multiple com-
parisons for primary and secondary endpoints; a similar
procedure was not applied to tertiary endpoints. Formal
testing of delayed-release DMF BID vs. placebo groups
was only undertaken if the analysis of delayed-release
DMF TID vs. placebo groups was statistically significant
(P B 0.05). Data obtained after patients switched to alter-
native MS medication were excluded. MRI lesion count
and PBVC endpoint analyses used all pre-switch data and
then imputed data after withdrawal or switching to a rescue
medication using a constant rate assumption. For MRI
1796 J Neurol (2014) 261:1794–1802
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volume data, missing data were imputed using the mean of
each treatment group at each visit.
Results
Patients
The disposition and baseline characteristics of the overall
ITT population (n = 1,234) have been reported previously
[12]. The MRI cohort comprised 540 patients in the ITT
population who were enrolled at sites that participated in
the MRI portion of the study (76 of 198 sites in 14
countries worldwide) and who had any MRI data: 180,
176, and 184 patients in the placebo, delayed-release DMF
BID, and delayed-release DMF TID groups, respectively
(Fig. 1). The MRI cohort displayed baseline characteris-
tics that were similar to the non-MRI cohort (Table e-1)
and the overall DEFINE ITT population [12], and were
broadly comparable across treatment groups (Table 1). In
both the MRI cohort and overall ITT population, 41 % of
patients had received prior approved disease-modifying
therapy. The mean time on study was 87.8, 85.8, and
82.2 weeks in the placebo, delayed-release DMF BID, and
delayed-release DMF TID groups of the MRI cohort,
respectively.
Lesion number and volume over 2 years
Full MRI cohort
Compared with placebo, delayed-release DMF treatment at
both doses resulted in statistically significant reductions in
the number of brain lesions at the first MRI assessment on
therapy (6 months), which were maintained to the end of
the study. Delayed-release DMF reduced the mean number
of new or enlarging T2-hyperintense lesions by 80 %
(BID) and 69 % (TID) at 6 months, by 84 % (BID) and
75 % (TID) at 1 year, and by 85 % (BID) and 74 % (TID)
at 2 years, compared with placebo (all P \ 0.0001;
Fig. 2a; Table e-2). Similar results in favor of delayed-
release DMF were seen for Gd? lesions (Fig. 2b; Table
e-3), with relative odds reductions of 94 % (BID) and 81 %
(TID) at 6 months, of 92 % (BID) and 87 % (TID) at
1 year, and of 90 % (BID) and 73 % (TID) at 2 years (all
P \ 0.0001). Delayed-release DMF reduced the mean
number of new non-enhancing T1-hypointense lesions by
58 % (BID; P \ 0.0001) and 48 % (TID; P = 0.0005) at
6 months, by 69 % (BID; P \ 0.0001) and 61 % (TID;
P \ 0.0001) at 1 year, and by 72 % (BID; P \ 0.0001) and
63 % (TID; P \ 0.0001) at 2 years, compared with pla-
cebo (Fig. 2c; Table e-4). At study end, 93 % of patients in
the BID group and 86 % in the TID group were free of
Fig. 1 Patient disposition: MRI cohort. BID twice daily, MS multiple sclerosis, TID three times daily
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Gd? lesions, compared with 62 % in the placebo group
(Table e-3).
These reductions in lesion number were paralleled by
reductions in lesion volume (Fig. 3a–c). Reductions in T2-
hyperintense and Gd? lesion volume were statistically
significant beginning from 6 months onward. From base-
line to 6 months, the median percentage change in T2-
hyperintense lesion volume with delayed-release DMF BID
and TID vs. placebo was -3.5 and -1.7 vs. ?1.6 % (BID,
P = 0.0002; TID, P = 0.0035); from baseline to 1 year,
the median percentage change was -5.8 and -3.7 vs.
?6.5 % (both P \ 0.0001); and from baseline to 2 years,
the median percentage change was -6.2 and -1.9 vs.
?20.1 % (both P \ 0.0001; Fig. 3a; Table e-2). At
6 months, the mean change in volume (mm3) of Gd?
lesions was -1.8, -203.2, and -118.7 for placebo,
delayed-release DMF BID, and delayed-release DMF TID,
respectively, which corresponds to a mean percentage
change of -95.0 % (BID) and -82.0 % (TID) vs.
?14.1 % (placebo; both P \ 0.0001) (Fig. 3b; Table e-3).
At 1 year, the mean change in volume (mm3) of Gd?
lesions was -12.6, -160.9, and -110.2 for placebo,
delayed-release DMF BID, and delayed-release DMF TID,
respectively, which corresponds to a mean percentage
change of -88.5 % (BID) and -65.9 % (TID) vs.
?97.4 % (placebo; both P \ 0.0001) (Fig. 3b; Table e-3).
At 2 years, the mean change in volume (mm3) of Gd?
lesions was ?15.1, -152.7, and -57.8 for placebo,
Table 1 Demographics and baseline characteristics of the MRI cohort
Characteristic Placebo (n = 180) Delayed-release
DMF BID (n = 176)
Delayed-release
DMF TID (n = 184)
Age, mean (SD) years 38.3 (9.16) 38.3 (9.31) 38.5 (8.59)
\40 years, n (%) 90 (50) 92 (52) 101 (55)
C40 years, n (%) 90 (50) 84 (48) 83 (45)
Female, n (%) 141 (78) 136 (77) 140 (76)
McDonald criteria for diagnosis
Criterion 1, n (%) 152 (84) 149 (85) 147 (80)
Criteria 2–4, n (%) 28 (16) 27 (15) 37 (20)
Previous approved disease-modifying therapy, n (%)a 77 (43) 68 (39) 74 (40)
Time since diagnosis, mean (SD) years 6.0 (5.76) 5.6 (5.54) 5.0 (4.96)
Relapses in previous year, mean (SD) 1.3 (0.73) 1.3 (0.64) 1.3 (0.57)
B1 relapse, n (%) 122 (68) 123 (70) 134 (73)
C2 relapses, n (%) 58 (32) 53 (30) 50 (27)
EDSS score, mean (SD)b 2.53 (1.25) 2.29 (1.17) 2.30 (1.19)
EDSS B2, n (%) 88 (49) 101 (57) 105 (57)
EDSS [2, n (%) 92 (51) 75 (43) 79 (43)
Number of T2 lesions, mean (SD) 49.2 (38.6) 47.6 (34.7) 55.8 (44.3)
T2 lesion volume, mean (SD) mm3 6,524.9 (7,601.50) 8,463.8 (10,058.73) 9,014.5 (11,769.21)
Number of Gd? lesions, mean (SD) 1.6 (3.45) 1.2 (3.30) 1.2 (4.10)
Patients with Gd? lesions, n (%)
0 lesions 103 (57) 117 (66) 124 (67)
1–4 lesions 55 (31) 47 (27) 49 (27)
5–8 lesions 13 (7) 5 (3) 7 (4)
C9 lesions 9 (5) 6 (3) 4 (2)
Unknown 0 1 (\1) 0
Number of T1-hypointense lesions, mean (SD) 27.3 (28.47) 27.8 (29.66) 33.6 (34.74)
Normalized whole brain volume, mean (SD) cm3 1,586.7 (81.7) 1,573.5 (85.8) 1,565.5 (93.1)
BID twice daily, EDSS Expanded Disability Status Scale, Gd? gadolinium-enhancing, TID three times daily
a Data shown for approved disease-modifying treatments only: interferon b-1a (29 % of all patients in the MRI cohort), glatiramer acetate
(18 %), interferon b-1b (12 %), and natalizumab (3 %). Patients may have received more than one prior disease-modifying treatment
b Scores on the EDSS range from 0 to 10, with higher scores indicating a greater degree of disability. Baseline score was[5.0 for one patient in
the placebo group and one patient in the TID group
1798 J Neurol (2014) 261:1794–1802
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delayed-release DMF BID, and delayed-release DMF TID,
respectively, which corresponds to a mean percentage
change of -79.0 % (BID) and -52.6 % (TID) vs.
?106.4 % (placebo; both P \ 0.0001) (Fig. 3b; Table e-3).
Reductions in T1-hypointense lesion volume were statis-
tically significant beginning from 1 year onward (BID) and
Fig. 2 Mean number (±95 % CI) of new or enlarging T2-hyperin-
tense lesions (a), Gd? lesions (b), and new T1-hypointense lesions
(c) at 6 months, 1 and 2 years. Patient numbers refer to those who
provided data both at baseline and at each scheduled MRI analysis.
Relative reductions (vs. placebo) in the risk of having a greater
number of Gd? lesions were based on the odds ratio from the pre-
specified analysis model of ordinal logistic regression (a conservative
method, chosen to minimize undue influence of outlier Gd? lesion
counts on the estimated treatment effect), for categories of patients
with 0, 1, 2, 3–4, and C5 lesions. Comparisons vs. placebo were based
on: (a) negative binomial regression, adjusted for region and baseline
lesion volume; (b) ordinal regression, adjusted for region and baseline
lesion number; (c) analysis of covariance on ranked data, adjusted for
region and baseline lesion volume. *P \ 0.05; **P \ 0.01;
P \ 0.001; §P \ 0.0001 vs. placebo. BID twice daily, CI confidence
interval, DMF dimethyl fumarate, Gd? gadolinium-enhancing, TID
three times daily
Fig. 3 Median percentage change in volume of T2-hyperintense
lesions (a), mean change from baseline in volume (mm3) of Gd?
lesions (b), and median percentage change in volume of T1-
hypointense lesions (c) at 6 months, 1 and 2 years. Patient numbers
refer to those who provided data both at baseline and at each
scheduled MRI analysis. Comparisons vs. placebo were based on
analysis of covariance on ranked data, adjusted for region and
baseline lesion volume. *P \ 0.05; **P \ 0.01; P \ 0.001;
§P \ 0.0001 vs. placebo. BID twice daily, DMF dimethyl fumarate,
Gd? gadolinium-enhancing, TID three times daily
J Neurol (2014) 261:1794–1802 1799
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at 2 years (TID). From baseline to 6 months, the median
percentage change in T1-hypointense lesion volume was
?1.5 and ?2.5 vs. ?4.3 % (both P [ 0.05); from baseline
to 1 year, the median percentage change was ?5.4 and
?4.7 vs. ?11.6 % (BID, P = 0.0126; TID, P [ 0.05); and
from baseline to 2 years, the median percentage change
was ?8.4 and ?12.7 vs. ?26.9 % (BID, P \ 0.0001; TID,
P = 0.0063; Fig. 3c; Table e-4).
The robustness of these findings was confirmed by
sensitivity analyses, based on all observed data, and on
observed data obtained prior to the start of alternative
therapy in patients who switched MS therapy (Figure e-1).
Patient subpopulations
The effect of delayed-release DMF on the mean number of
new or enlarging T2-hyperintense lesions and on the
number of Gd? lesions was consistent across a range of
pre-specified patient subpopulations. In patients stratified
by baseline characteristics (gender, age\40 vs. C40 years,
B1 vs. C2 relapses in the year prior to study, McDonald
criteria, prior MS treatment, EDSS score, T2-hyperintense
lesion volume, and Gd? lesion status), results showed
consistent reductions in lesion numbers with either dose of
delayed-release DMF compared with placebo (Figure e-2).
Brain atrophy
The median PBVC in the placebo group was -0.81 %
from baseline to 2 years and -0.66 % from 6 months to
2 years (Fig. 4; Table e-5). Delayed-release DMF BID and
TID attenuated brain volume loss from baseline to 2 years
by 21 % (P = 0.0449) and 5 % (P = 0.6398), respec-
tively, compared with placebo. Similar results were
observed from 6 months to 2 years with relative reductions
of 30 % (P = 0.0214) and 17 % (P = 0.2478) with
delayed-release DMF BID and TID, respectively.
Discussion
Among the results of the DEFINE study were the findings
that delayed-release DMF significantly reduced the number
of new or enlarging T2-hyperintense lesions and Gd?
lesions at 2 years compared with placebo, suggesting
reductions in both the inflammatory processes that corre-
late with MS relapses and the burden of focal white matter
disease [12]. The analysis presented here expands on these
results by assessing the effects of delayed-release DMF on
additional MRI measures, providing information on the
time course of these effects, and evaluating the generality
of the effects across a diverse patient population. Reduc-
tions in the number of new or enlarging T2-hyperintense
lesions and Gd? lesions in patients treated with delayed-
release DMF compared with placebo were observed as
early as the first scheduled MRI assessment at 6 months
and were sustained at 1 and 2 years; reductions were also
seen in the number of T1-hypointense lesions at 6 months,
1 and 2 years. Compared with placebo, delayed-release
DMF reduced the volume of T2-hyperintense and Gd?
lesions beginning at 6 months and the volume of T1-hyp-
ointense lesions beginning at 1–2 years. In support of these
findings, analyses of brain atrophy revealed a significant
reduction in PBVC from 6 months to 2 years in patients
treated with delayed-release DMF BID compared with
placebo. The effects on delayed-release DMF on the
number of new or enlarging T2-hyperintense lesions and
Gd? lesion activity were seen across patient subpopula-
tions representing a broad range of demographic and dis-
ease characteristics. The validity of these findings is further
supported by sensitivity analyses using observed data
without imputation. Altogether, the reductions in MRI
disease activity with delayed-release DMF treatment are
suggestive of an early decrease in brain inflammation and
reduction of tissue destruction and axonal loss associated
with the progression of disability.
The observations in DEFINE are consistent with those
seen in a Phase 2 dose-ranging study, in which delayed-
release DMF 240 mg TID significantly reduced the mean
total number of new Gd? lesions by 69 % from 3 to
6 months, compared with placebo [3]. The results of the
present study are also consistent with those reported in
CONFIRM, in which delayed-release DMF BID and TID
treatment reduced the mean number of new or enlarging
T2-hyperintense lesions by 71 and 73 %, Gd? lesion
Fig. 4 Median percentage change in whole brain volume at 2 years
relative to baseline and 6 months. Comparisons vs. placebo were
based on analysis of covariance on ranked data, adjusted for region
and normalized brain volume at 6 months. *P \ 0.05 vs. placebo.
BID twice daily, DMF dimethyl fumarate, TID three times daily
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activity by 74 and 65 %, and the mean number of new T1-
hypointense lesions by 57 and 65 %, respectively (all
P \ 0.001) [13]. The reductions in lesion number with
delayed-release DMF relative to placebo were generally
greater than those seen with glatiramer acetate, used as a
reference comparator in CONFIRM [13]. The effects of
delayed-release DMF on MRI lesion outcomes in the
present study are comparable with, or in some cases
exceed, those of other oral [6, 7, 18, 19] and parenteral [20,
21] disease-modifying therapies in 2-year, Phase 3 RRMS
studies, although cross-study comparisons should be
interpreted with caution due to differences in study design,
population, and MRI methodology.
Examination of a range of study subpopulations defined
by baseline disease characteristics or demographics showed
that delayed-release DMF treatment conferred MRI bene-
fits across patient groups with RRMS, a result that expands
on the observed decrease in new Gd? lesion development
seen across subgroups in the Phase 2 study [18] and is
consistent with findings in the CONFIRM study [13].
Measurements of brain atrophy continue to be an area
with evolving methodologies. Reported slowing of rates of
atrophy with disease-modifying therapies may vary
depending on the therapy [22], whether the rate of atrophy
is expressed using whole brain volume as the denominator
(FREEDOMS [23] and ALLEGRO studies [20]) or brain
parenchymal fraction (AFFIRM [24] and TEMSO [25]),
and with the method used to measure the atrophy [26].
Even when utilizing the same overall methodology, the
area of the brain included in the calculation can differ, for
example, if the MRI scans do not provide full brain cov-
erage [21]. Thus, comparing across trials for this endpoint
is especially problematic. Despite a low rate of brain
atrophy in the placebo group in DEFINE, a beneficial and
statistically significant effect on atrophy was seen with the
BID dose regimen at 2 years when evaluated either from
baseline or from 6 months. Although not observed in this
study, some therapies for MS have shown greater decreases
in brain volume compared with placebo in the first months
following initiation of treatment, a phenomenon sometimes
referred to as ‘pseudoatrophy’. However, the mechanisms
responsible for this are unclear, and despite considering
this effect to be related to decreasing brain inflammation, it
is not always seen in clinical trials of agents with potent
anti-inflammatory effects [21].
Conclusion
Overall, expanded results of MRI analyses from the
DEFINE study demonstrate rapid efficacy of delayed-
release DMF in terms of reduced lesion number and vol-
ume compared with placebo, consistent with evidence from
a Phase 2 study [3] and the Phase 3 CONFIRM study [13].
Reductions in lesion counts and volume, together with
supportive data on brain atrophy, are consistent with the
hypothesis that delayed-release DMF favorably affects
multiple aspects of MS pathophysiology.
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